Vetalgin

Quick links to important sections

Vetalgin

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vetalgin

Quick Facts

Property Description
Active ingredient Metamizole Sodium (Dipyrone)
Pharmacological class Non-opioid Analgesic, Antipyretic, Spasmolytic
Origin Synthetic (Pyrazolone derivative)
Common purpose Management of moderate-to-severe pain and high fever
Forms Tablet, Oral drops, Injection solution, Suppository

What Type of Medicine is Vetalgin (Metamizole Sodium)?

Vetalgin is a synthetic, single-ingredient medication whose active substance is Metamizole Sodium, also widely known as Dipyrone. This potent compound is chemically derived from the pyrazolone family. The medicine is officially classified as a Non-opioid analgesic and Antipyretic, setting it apart from typical NSAIDs and simple analgesics. This specific classification establishes Vetalgin as a robust, non-narcotic option typically reserved for situations requiring stronger intervention than over-the-counter options can provide.

Core Purpose: Pain, Fever, and Cramp Management

The overall purpose of Vetalgin is to deliver comprehensive symptomatic relief, stemming from its characteristic combination of analgesic (pain-relieving), antipyretic (fever-reducing), and spasmolytic (cramp-relieving) properties. The medication’s efficacy is clinically recognized for its unique profile, making it a valuable option when pain is coupled with involuntary muscle contractions. The clinical profile of Metamizole includes antispasmodic efficacy in treating abdominal pain. This highlights the drug's added benefit in relaxing smooth muscles, distinguishing it from most standard analgesics.

Available Preparations and Administration Types

Metamizole Sodium is produced in multiple forms, ensuring adaptability for patient needs and setting. Dosage forms include tablets and oral drops for oral use, suppositories for rectal administration, and an injection solution intended for both intramuscular and intravenous administration. This versatility ensures that a suitable preparation is available regardless of the clinical requirement, allowing Vetalgin to be administered rapidly in acute settings or through sustained oral and rectal routes.

Regulatory References

  1. Metamizole: LiverTox - NIH

What side effects are possible with Vetalgin?

Safety Profile Overview

Vetalgin, which contains the active substance Metamizole sodium, has a documented safety profile derived from governmental regulatory documents, primarily focusing on potential serious adverse reactions and administration precautions. The most significant safety concerns involve the haematopoietic system (blood disorders) and the risk of hypersensitivity reactions.


Documented Side Effects and Adverse Reactions

The primary serious adverse reaction associated with the use of Metamizole is the potential for agranulocytosis (a severe reduction in white blood cells) and other haematological profile changes (e.g., leukopenia). These effects are generally linked to prolonged administration at high dose rates.

Other adverse outcomes documented in regulatory texts include:

  • Gastrointestinal effects: Irritation or haemorrhage in the gastrointestinal tract, especially with prolonged high-dose treatment.
  • Immune System: Potential for shock (anaphylactic reaction), particularly following very fast intravenous injection.
  • Local Reactions: Tissue irritation if the product is administered via the subcutaneous route (a route explicitly advised against).
  • Renal Impairment: Potential for impaired renal function following prolonged, high-dose exposure.

Restrictions and Safety Limitations

The product is contraindicated in certain animals and under specific medical conditions to manage risk. It must not be used in animals with pre-existing disorders of the haematopoietic system, gastrointestinal ulcers, chronic gastrointestinal disorders, or conditions such as renal insufficiency or bronchial asthma.

Safety mandates require that intravenous injection be performed very slowly to mitigate the potential for shock. Furthermore, Vetalgin is contraindicated in cats.

Overdose and Emergency Response

Overdose and when to seek help

The information below outlines the officially documented clinical manifestations and emergency actions mandated by regulatory authorities concerning Vetalgin (Metamizole Sodium) overexposure.

Documented Overdose Manifestations

An acute overdose may present with Central Nervous System (CNS) effects including somnolence, agitation, vertigo, convulsions, and potentially progressing to coma. Severe poisoning also affects the cardiovascular system, causing marked hypotension (blood pressure decrease) and circulatory shock, alongside tachycardia. Gastrointestinal symptoms such as nausea, vomiting, and abdominal pain are common. Significant overexposure can lead to life-threatening outcomes including Acute Kidney Failure, Acute Liver Failure, and severe metabolic disturbances like acid-base imbalance.

Required Emergency Actions

Seek immediate medical attention for any suspected overdose or acute overexposure. Official guidance dictates that immediate hospitalization and monitoring are required for severe cases. Management involves symptomatic and supportive treatment, including measures to limit absorption such as activated charcoal if administered within one to two hours of ingestion. No specific antidote is known for Metamizole overdose. Additionally, patients must stop the medicine and seek urgent medical assistance if symptoms of agranulocytosis occur (e.g., persistent fever, sore throat, or mucosal ulcers), as this is a separate, life-threatening regulatory trigger.

Therapeutic Uses of Vetalgin

This medication contains an active component classified as part of the pyrazolone group of analgesics and antipyretics. It is commonly used when short-term symptomatic assistance is needed across a range of conditions.

Addressing Episodes of Symptomatic Discomfort

This treatment is applied across domains where additional symptomatic support is needed in situations involving distressing symptoms related to physical discomfort and systemic imbalance. It provides support that helps ease the overall burden of symptoms and supports the patient during difficult episodes by easing distress. The treatment is commonly used to help with symptoms related to physical discomfort and symptoms of increased neurological or muscular activity.


Management of Disruptive Symptom Patterns

The treatment is relevant for addressing symptom clusters that may become intense or disruptive, including symptoms that create noticeable functional strain or interfere with daily comfort. This supportive relief may assist with the goal of maintaining functional stability when symptoms become temporarily overwhelming. Quick Fact: Supports Management of Episodic Discomfort


Support for Acute and Recurrent Symptom Manifestations

Generally used across conditions characterized by periods of heightened symptoms or episodic manifestations, it is commonly used when symptoms escalate temporarily and supportive relief is needed. It contributes to improved day-to-day comfort during symptomatic periods. It may be part of symptomatic management in situations involving acute or disruptive episodes where additional assistance is helpful.

Eligibility and Restrictions for Use

Vetalgin (Metamizole Sodium) is subject to strict eligibility rules established by regulatory authorities. The medicine is contraindicated and must not be used by patients with a documented history of Metamizole-induced blood disorders, such as agranulocytosis, or those with impaired bone marrow function. Non-eligibility also extends to specific metabolic conditions, including acute intermittent hepatic porphyria and congenital glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Use is also strictly limited by age and reproductive status. It is contraindicated in infants below three months of age or under 5 kg body weight. Use is prohibited during the third trimester of pregnancy due to official risks to the fetus and is generally not recommended during the first and second trimesters. For breastfeeding, repeated use is avoided; a single dose requires breastmilk to be discarded for 48 hours.

Conditional use is required for the elderly and for patients with impaired hepatic or renal function, often necessitating reduced dosing as described in the official label. Furthermore, individuals with analgesic-induced asthma or chronic urticaria must use the medicine with extreme caution due to a special regulatory designation of heightened risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation outlines specific pharmacokinetic and pharmacodynamic interactions for Vetalgin (Metamizole Sodium).

Documented Interaction Patterns

Interaction Type Co-administered Substance Documented Outcome
Exposure Decrease Ciclosporin Plasma concentration and overall exposure are reduced.
Toxicity Increase Methotrexate Concentration is increased, elevating the risk of haematologic toxicity.
Functional Interference Low-dose Acetylsalicylic Acid (Aspirin) The anti-platelet effect is inhibited.
Additive Risk Chlorpromazine Risk of severe hypothermia.

Pharmacokinetic Mechanisms and Restrictions

Vetalgin's main active metabolite is formally documented as a moderate to strong inducer of several liver enzymes, including CYP3A4, CYP2B6, and CYP2C19. This induction mechanism is associated with a reduction in the plasma concentration of other medicines metabolized by these enzymes. Conversely, the metabolite is also a weak inhibitor of CYP1A2, which can lead to increased concentrations of its substrates.

To preserve the anti-platelet effect of low-dose aspirin, official regulatory information mandates a separation in the timing of administration of the two medicines. Additionally, the drug may decrease the activity of certain co-administered antihypertensive medicines.

Mechanism of Action

Vetalgin's active substance, metamizole, is a pro-drug that undergoes rapid hydrolysis to its primary active metabolite, 4-methylaminoantipyrine (MAA), which subsequently metabolizes to 4-aminoantipyrine (AA) and inactive moieties. The pharmacological action is primarily attributed to MAA and AA.

The analgesic action involves the central nervous system (CNS), where MAA and AA metabolites penetrate the blood-brain barrier. MAA is proposed to function as an inhibitor of central cyclooxygenase-3 (COX-3), an enzyme predominantly expressed in the CNS, leading to reduced synthesis of prostaglandin E2 (PGE2) in the brain. This central inhibition modulates the transmission of nociceptive signals. Additionally, MAA and AA are suggested to be agonists of the cannabinoid receptor type 1 ( CB1), which is associated with descending antinociceptive pathways in the periaqueductal gray matter. Activation of CB1 receptors can modulate gamma-aminobutyric acid (GABA) transmission, contributing to systemic analgesia.

Separately, metamizole exerts a spasmolytic effect on smooth muscle tissue. This action is thought to be mediated by an intracellular cascade involving the inhibition of inositol phosphate synthesis, which results in the reduced release of intracellular Ca^2+ stores in smooth muscle cells.

Dosage and Administration Information

Vetalgin (Metamizole Sodium) is authorized for several administration pathways, including oral (drops, tablets), rectal (suppositories), intramuscular (IM), and intravenous (IV) routes. This range of administration methods is defined to suit various settings and patient needs.

Use of the medicine is typically initiated at the lowest possible single dose, which is subsequently adjusted based on the intensity of the symptoms. For adults, the typical single oral dose ranges from 500 mg up to 1,000 mg. The total daily intake is limited, with a maximum of 4,000 mg for oral use and 5,000 mg for injectable administration.

Dosing is typically conducted for short-term treatment on an as-needed basis (p.r.n.), with administration not to exceed 4 times daily. A minimum interval of 6–8 hours is maintained between subsequent doses.

The administration technique is also specified: intravenous delivery is performed as a slow injection or infusion. Dosing for children (up to 14 years) is calculated precisely based on body weight, following an 8–16 mg per kg guideline. Furthermore, a dose reduction is required for older adults, debilitated patients, and individuals with reduced renal or hepatic function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vetalgin (Metamizole Sodium)


Evidence for Use in Acute Pain and Post-Operative Settings

Research exploring Vetalgin was studied for outcomes related to physical discomfort, primarily relying on Randomized Controlled Trials (RCTs). These are commonly relied upon study designs. In these studies, Vetalgin was studied for use in conditions where symptoms may vary in intensity, such as acute pain following various surgical procedures. Researchers monitored outcomes related to physical discomfort using standardized scales and tracked the need for additional pain medication. The findings describe patterns observed in the studies related to measurements of pain intensity shortly after a dose was administered.

Short-Term Studies vs. Standard Pain Management

This sub-section clarifies the study design of the short-term analgesic trials, detailing how Vetalgin's use was observed alongside placebo or other standard pain management options. These comparison studies help contextualize how patients reported their experience when Vetalgin was studied for conditions involving periods of heightened symptoms.


Evidence for Use in High Fever Management

Vetalgin was studied for its use as an antipyretic agent in studies focusing on episodes where symptoms become more noticeable due to high temperature. The research primarily consists of RCTs and Systematic Reviews. These studies monitored physiological strain, with the main outcome measured being the absolute temperature change from the starting point at set time intervals. Findings indicate patterns related to a measured change in temperature, typically observed shortly after administration.


Research Focus on Special Populations

Clinical data show patterns related to Vetalgin being evaluated in multiple patient groups. In children, research has been conducted to understand how the body processes the medication (pharmacokinetic studies) following elective surgery, which contributes to the understanding of administration in this age group. Older adults are frequently represented in the observational data, particularly in studies examining real-world usage patterns in conditions marked by functional limitations.


Long-Term Evidence and Follow-Up

Research examined outcomes related to episodic or acute changes and short-term symptom patterns. Follow-up durations were limited in the majority of randomized controlled trials. Long-term effects are not fully established. While observational data exists in chronic pain settings that cover intermediate-to-long term usage, the research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted. There is limited information for long-term outcomes, especially regarding the durability of effects.

Key Studies & References

  1. Short-term use of metamizole sodium versus diclofenac sodium in acute renal colic pain in Turkish patients
  2. Metamizole [Dipyrone] - LiverTox - NCBI Bookshelf - NIH (Observational/Safety Context)

Frequently Asked Questions (FAQ)

Common questions about Vetalgin (FAQ)


Q: How quickly should I feel an effect after taking Vetalgin?

Based on pharmacokinetic studies, after Vetalgin is taken orally, the concentration of the main active substance in the blood is expected to reach its maximum between 1.4 and 2.0 hours. This time frame corresponds to the documented average time for the primary active substance to reach its peak concentration in the blood.


Q: How long does Vetalgin stay in your system?

Regulatory data reports the half-life of the primary active metabolite (MAA) to be between 2.6 and 3.5 hours. The half-life is a measure of the time required for the concentration of the substance in the body to be reduced by half.


Q: Is Vetalgin similar to Tylenol or ibuprofen?

Official documents state that the active substance, Metamizole, does not follow the same mechanism of action as conventional NSAIDs (like ibuprofen). Vetalgin is formally classified as a non-opioid analgesic, antipyretic, and spasmolytic agent.


Q: What are the general expectations for Vetalgin's overall action?

Official documents classify Vetalgin as a medication with three primary actions. These are strong analgesic (pain-relieving), antipyretic (fever-reducing), and spasmolytic (cramp-relieving) properties.


Q: Can Vetalgin be taken by people with kidney issues (high-level question)?

Official information advises discussing any pre-existing kidney disease with a healthcare professional prior to use. Patients with impaired renal function are a special population where specific administration adjustments are officially required.


Q: Are there any specific foods to avoid when using Vetalgin?

While specific foods are not listed for avoidance, official regulatory information contains an advisory statement against the consumption of alcohol while using this medicine.


Q: Is it common for people to feel tired when they start Vetalgin?

Yes, official safety documentation lists both fatigue and drowsiness as potential side effects of the medication.


Q: Can Vetalgin be used if I am taking supplements like vitamins or herbal products?

Official patient information describes the importance of communicating with a healthcare professional about all products. This includes herbal products, supplements, and non-prescription medicines, due to the potential for interactions.


Q: Is Vetalgin available over-the-counter in some countries?

The regulatory status of Vetalgin (Metamizole) varies significantly across regions. In some areas, it is available only by prescription, while in other countries, it may be authorized as an over-the-counter (OTC) preparation.


Q: Do children or teenagers ever use Vetalgin?

Yes, regulatory guidelines confirm that specific administration instructions are established for children (typically up to 14 years old). Contraindications for use are typically applied to infants below three months of age.


Q: Does Vetalgin cause any digestive problems?

Documented side effects affecting the digestive system include nausea, vomiting, and discomfort or pain in the stomach.


Q: Is Vetalgin safe for older adults (high-level question)?

Older adults are classified as a special population where a dose reduction is formally required in the administration instructions. This is due to age-related changes in how the body processes the medication, and caution is advised.


Q: Are there warnings about driving or operating machinery while on Vetalgin?

Official patient warnings describe limitations on activities that require full alertness, such as driving or operating machinery. This is due to the documented potential for side effects like drowsiness and low blood pressure.


Q: Can Vetalgin affect birth control pills?

Regulatory information indicates that Vetalgin may reduce the effectiveness of hormonal contraceptives, which may necessitate a review of contraceptive methods.


Q: Are headaches a listed side effect of Vetalgin?

Yes, headaches are listed in regulatory documents as a possible side effect, usually grouped under disorders of the nervous system.


Q: Can Vetalgin make existing health conditions worse?

The medicine is contraindicated (should not be used) in patients with specific pre-existing conditions, such as certain blood disorders, metabolic issues, or severe kidney impairment. These restrictions are in place because use may pose a risk.


Q: Are there any warnings about combining Vetalgin with alcohol?

Official patient information contains a clear advisory statement against the consumption of alcohol while using this medicine.


Q: Why is Vetalgin sometimes called by different names?

Vetalgin’s active substance, Metamizole Sodium, is also widely known by other chemical names, such as Dipyrone or Noramidopyrine. This nomenclature depends on the regional classification and the trade name used locally.


Q: What is the risk profile of Vetalgin compared to its expected purpose?

The medication is valued for its three primary actions (analgesic, antipyretic, spasmolytic). It is often noted as having a favorable gastrointestinal and cardiovascular side effect profile compared to traditional NSAIDs, though it carries specific, known warnings for blood disorders (agranulocytosis).


Q: Is the research evidence for Vetalgin considered strong?

Official data shows that research supporting its use relies heavily on Randomized Controlled Trials (RCTs) and Systematic Reviews. These are specific study designs commonly relied upon in medical science to evaluate the effects of a treatment.


Q: Can Vetalgin cause skin rashes?

Skin rashes and other serious skin and subcutaneous disorders are listed as documented adverse effects in regulatory documentation. These reactions may be related to hypersensitivity.


Q: Is Vetalgin used for muscle spasms?

Yes, in addition to pain and fever reduction, the medicine has spasmolytic (cramp-relieving) properties. Because of this action, it is used to treat muscle spasms.


Q: Are there special considerations for people with heart disease and Vetalgin?

Official guidance describes the need for careful monitoring in patients with conditions like severe coronary artery disease, particularly where the avoidance of sudden blood pressure changes is a concern.


Q: Does Vetalgin contain gluten or common allergens?

Official documentation advises that individuals with known allergies or sensitivities should consult the excipient list (inactive ingredients) for their prescribed preparation, as formulations may contain substances like corn starch.


Q: Is there a maximum time Vetalgin is typically used for?

Regulatory information indicates the medicine is typically intended for short-term treatment on an as-needed basis. Some safety data suggests that courses of less than 2 weeks are associated with a lower frequency of adverse events.


Q: Has Vetalgin been approved by the FDA?

The active substance, Metamizole (Dipyrone), is not approved for marketing by the U.S. Food and Drug Administration (FDA). This is due to regulatory concerns over adverse reactions, such as agranulocytosis.

How should Vetalgin be stored and disposed of?

How to Store and Dispose of Vetalgin

Official regulatory information defines mandatory conditions for storing and disposing of Vetalgin (Metamizole) to ensure product stability and environmental safety.

Storage Requirements

Condition Type Official Requirement
Temperature Store below 30 C (or 25 C, as specified by the label).
Protection Keep in the original container or outer carton to protect from light and moisture.
Handling The product must not be refrigerated or frozen.
Child Safety Store out of the sight and reach of children.
Stability Adhere to the documented expiry date and any in-use stability period after first opening.

Disposal Instructions

Do not dispose of Vetalgin via household waste or wastewater (e.g., flushing down the toilet or sink). Unused or expired medication must be returned to a community drug take-back program or a pharmacy for proper disposal to prevent environmental contamination, according to local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vetalgin found in:

A-Z Index: